The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER?
Abstract
PURPOSE: The association of free and total testosterone with prostate cancer is incompletely understood. We investigated the relationship of serum free and total testosterone to the clinical and pathological characteristics of prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed the clinical records of 117 consecutive patients treated by 1 physician and diagnosed with prostate cancer at our medical center between 1994 and 1997. Low free and total testosterone levels were defined as 1.5 or less and 300 ng./dl., respectively. RESULTS: After evaluating all 117 patients we noted no correlation of free and total testosterone with prostate specific antigen, patient age, prostatic volume, percent of positive biopsies, biopsy Gleason score or clinical stage. However, in patients with low versus normal free testosterone there were an increased mean percent of biopsies that showed cancer (43% versus 22%, p = 0.013) and an increased incidence of a biopsy Gleason score of 8 or greater (7 of 64 versus 0 of 48, p = 0.025). Of the 117 patients 57 underwent radical retropubic prostatectomy. In those with low versus normal free testosterone an increased mean percent of biopsies demonstrated cancer (47% versus 28%, p = 0.018). Pathological evaluation revealed stage pT2ab, pT2c, pT3 and pT4 disease, respectively, in 31%, 64%, 8% and 0% of patients with low and in 40%, 40.6%, 12.5% and 6.2% in those with normal free testosterone (p>0.05). CONCLUSIONS: In our study patients with prostate cancer and low free testosterone had more extensive disease. In addition, all men with a biopsy Gleason score of 8 or greater had low serum free testosterone. This finding suggests that low serum free testosterone may be a marker for more aggressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Occult Prostate Cancer in Men With Low Serum Testosterone Levels
Morgentaler, A. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540230054035 · Cited by 279
Self-citationTENOVER, J. S., MATSUMOTO, A. M., PLYMATE, S. R., & BREMNER, W. J. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-6-1118 · Cited by 256
INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELS
MILLER, L. R., PARTIN, A. W., CHAN, D. W., BRUZEK, D. J., DOBS, A. S., EPSTEIN, J. I., & WALSH, P. C. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62922-7 · Cited by 177
Longitudinal evaluation of serum androgen levels in men with and without prostate cancer
Carter, H. B., Pearson, J. D., Metter, E. J., Chan, D. W., Andres, R., Fozard, J. L., Rosner, W., & Walsh, P. C. (1995) · The Prostate · doi:10.1002/pros.2990270106 · Cited by 138
Mitchell, R. M., Hollls, S., Rothwell, C., & Robertson, W. R. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02669.x · Cited by 95
SERUM STEROIDS IN NORMAL MALES AND PATIENTS WITH PROSTATIC DISEASES
Hammond, G. L., Kontturi, M. J., Vihko, P., & Vihko, R. (1978) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1978.tb02189.x · Cited by 87
Analysis of Prognostic Factors in Men with Metastatic Prostate Cancer
Ernst, D. S., Hanson, J., Venner, P. M., & Uro-Oncology Group of Northern Alberta (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)37797-2 · Cited by 69
Monath, J. R., McCullough, D. L., Hart, L. J., & Jarow, J. P. (1995) · Urology · doi:10.1016/s0090-4295(99)80159-9 · Cited by 54
Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma.
Iversen, P., Rasmussen, F., & Christensen, I. J. (1994) · PubMed · Cited by 51
Monda, J. M., Myers, R. P., Bostwick, D. G., et al. (1995) · Urology · doi:10.1016/s0090-4295(99)80160-5 · Cited by 49
Cited by
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
High‐grade prostate cancer is associated with low serum testosterone levels
Schatzl, G., Madersbacher, S., Thurridl, T., Waldmüller, J., Kramer, G., Haitel, A., & Marberger, M. (2001) · The Prostate · doi:10.1002/pros.1046 · Cited by 334
MASSENGILL, J. C., SUN, L., MOUL, J. W., WU, H., McLEOD, D. G., AMLING, C., LANCE, R., FOLEY, J., SEXTON, W., KUSUDA, L., et al. (2003) · Journal of Urology · doi:10.1097/01.ju.0000062674.43964.d0 · Cited by 293
Discacciati, A., Orsini, N., & Wolk, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr603 · Cited by 278
Metadata
- Authors
- HOFFMAN, M. A., DeWOLF, W. C., & MORGENTALER, A.
- Venue
- Journal of Urology
- Published
- 2000-03
- Volume
- 163
- Issue
- 3
- Pages
- 824-827
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1983712096
- Cited by
- 322
- References
- 12
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER? https://app.cochat.ai/papers/10.1016/s0022-5347(05)67812-3
- The paper
- HOFFMAN, M. A., DeWOLF, W. C., & MORGENTALER, A. (2000). IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER? Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67812-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.